JB

Jim R. Beitel

BP Biomarin Pharmaceutical: 9 patents #17 of 139Top 15%
📍 Novato, CA: #94 of 607 inventorsTop 20%
🗺 California: #60,666 of 386,348 inventorsTop 20%
Overall (All Time): #505,041 of 4,157,543Top 15%
10
Patents All Time

Issued Patents All Time

Showing 1–10 of 10 patents

Patent #TitleCo-InventorsDate
10793894 Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Robin M. Jackman 2020-10-06
10677786 Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Robin M. Jackman 2020-06-09
10260084 Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Robin M. Jackman 2019-04-16
9915649 Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Robin M. Jackman 2018-03-13
9677116 Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Robin M. Jackman 2017-06-13
9340822 Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Robin M. Jackman 2016-05-17
9222120 Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Brett E. Crawford, Jilllian R. Brown, Charles A. Glass, Robin M. Jackman 2015-12-29
8809009 Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Robin M. Jackman 2014-08-19
8771974 Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Robin M. Jackman 2014-07-08
8232073 Quantification of non-reducing end glycan residual compounds Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Robin M. Jackman 2012-07-31